Selegiline

Selegiline (Deprenyl) is a potent, selective and irreversible inhibitor of MAO-B, with an IC50 of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC50=23 μM) . Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder[1][2][3].

Product Specifications

CAS Number

[14611-51-9]

Product Name Alternative

Deprenyl; (-) -Selegiline; (-) -Deprenyl

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/selegiline.html

Solubility

10 mM in DMSO

Smiles

CN(CC#C)[C@H](C)CC1=CC=CC=C1

Molecular Formula

C13H17N

Molecular Weight

187.28

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Chaurasiya ND, et, al. Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana) . Molecules. 2019 Feb 23;24 (4) :810.|[2]Tatton WG, et, al. Modulation of gene expression rather than monoamine oxidase inhibition: (-) -deprenyl-related compounds in controlling neurodegeneration. Neurology. 1996 Dec;47 (6 Suppl 3) :S171-83.|[3]MohanKumar PS, et, al. Deprenyl stimulates the efflux of monoamines from the rat hypothalamus in vitro. Brain Res Bull. 2001 Apr;54 (6) :675-80.|[4]Ho MC, et, al. Chronic treatment with monoamine oxidase-B inhibitors decreases cocaine reward in mice. Psychopharmacology (Berl) . 2009 Jul;205 (1) :141-9.